TYRA (Tyra Biosciences Inc) שולי הרווח הגולמי

Tyra Biosciences, Inc. (TYRA) is developing unique molecules to combat cancer resistance, driving an increase in share prices. Gross margin profitability confirms this trend, where the value of 0.00 reflects this status. The business relies on the success of FGFR clinical trials, while the targeted therapy sector demonstrates high resilience to economic cycles.
פילוחי מדדים פיננסיים ומדדי שוק עבור Tyra Biosciences, Inc. (TYRA)

For the research startup Tyra Biosciences (TYRA), whose costs are limited to laboratory expenses and reagent disposal, the gross margin reflects the efficiency of managing direct development costs. This indicator measures the portion of revenue remaining after deducting the cost of goods sold, allowing investors to assess the product's internal profitability by analyzing the gross margin chart for the business model's resilience to operational risks.